{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000157","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.928545+00:00","generated_at":"2026-05-28T03:43:17.770427+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M","bullets":["Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).","2025 net revenue guidance of $820-860M, implying continued growth toward $1B+ opportunity.","Pipeline catalysts: FDA decision on pitolisant sNDA for idiopathic hypersomnia expected Q1 2025; potential approval in 2025.","Phase 3 topline data for ZYN002 in Fragile X syndrome expected Q3 2025; Pitolisant-HD Phase 3 in narcolepsy to start Q4 2025.","Average patients on WAKIX increased to ~7,100 in Q4 2024, up ~300 sequentially."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000157","json":"https://secwatch.observer/filing/0001558370-25-000157.json","markdown":"https://secwatch.observer/filing/0001558370-25-000157.md","text":"https://secwatch.observer/filing/0001558370-25-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/0001558370-25-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/hrmy-20250113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:43:17.770427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}